The case for cost sharing for biologic therapies
Meyers Primary Care Institute
Biological Agents; Cost Sharing; Cost-Benefit Analysis; Drug Costs; Humans; Managed Care Programs; Patient Participation; United States
Health Services Research | Pharmacy and Pharmaceutical Sciences | Primary Care
Although there were few users of biologics in the past, today many more common conditions, such as rheumatoid arthritis, asthma, and hepatitis C, are being treated with biologics. Payers must be able to determine the true cost benefit of a therapy and provide this information to patients.
Am J Manag Care. 2006 Apr;12(6 Suppl):S159-61; discussion S167-72; quiz S173-6.
The American journal of managed care
Fish, Leslie S., "The case for cost sharing for biologic therapies" (2006). Meyers Primary Care Institute Publications and Presentations. 535.